Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe
Advicenne (Euronext: ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces it has entered into a partnership with the European Society for Paediatric Nephrology (ESPN). This partnership, which will initially last for 3 years, will enable data collection on distal Renal Tubular Acidosis (dRTA) in Europe.
This collaboration will be marked by the opening of a survey on the management of dRTA in Europe (mainly covering the 5 largest European countries). The database will gather real-life data on health evolution and care process of 400 dRTA patients with primarily the genetic form of the disease in Europe. The database will be used to provide compelling information on patient journey, diagnostic, alternative treatments and complications arising from dRTA. Data collected will be published to publications with the objective to share its findings with the health community.
Elena Levtchenko, ESPN Secretary General comments: “This partnership reflects our willingness to improve the knowledge available around renal diseases that affect children, and in this case around dRTA. The information gathered will allow us to improve patient journeys and quality of care of patients affected by dRTA in Europe.”